Dr. Brezski brings over 25 years of experience in antibody science, with expertise in B cell immunology, antibody engineering, and computational molecular design.
He earned his PhD in Immunology from the University of Pennsylvania, investigating B cell antigen receptor structure and function in the context of immune tolerance. Following a Johnson & Johnson Corporate Office of Science and Technology fellowship at Centocor, he advanced through roles of increasing scientific leadership, ultimately co-founding and leading a Janssen Innovation Incubator.
At Genentech in the Antibody Engineering Department, Dr. Brezski led an antibody discovery team and served as Molecular Lead for multiple programs across diverse therapeutic areas including oncology, immunology, neuroscience, and metabolic diseases.
For the past three years, he has operated as an independent consultant supporting early-stage biotechnology companies from discovery through IND-enabling studies. Dr. Brezski’s work has contributed to the advancement of multiple biologics into clinical development.
Dr. Brezski has authored over 30 peer-reviewed publications, holds more than 10 patents, and served as assistant editor for mAbs for seven years. He is currently pursuing graduate studies in computational molecular science at the University of California, Berkeley, expanding his expertise in computational antibody design and bioinformatics.
Randy brings a distinctive combination of deep antibody engineering expertise and computational innovation, including database development, with a commitment to expanding knowledge across the antibody research community.
This blend of technical depth and collaborative approach positions him well to strengthen our business intelligence and engagement initiatives. We’re particularly excited to welcome a colleague whose work reflects both scientific rigor and genuine enthusiasm for connecting and supporting researchers at all career stages.
